NCT02435238 (AWARE) is a clinical trial in Chronic Urticaria, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02435238?

NCT02435238 is sponsored by Novartis Pharmaceuticals.

What condition does NCT02435238 study?

NCT02435238 studies Chronic Urticaria.

Is NCT02435238 still recruiting?

NCT02435238 is currently completed. Last updated 15 February 2018.

Last reviewed 2018-02-15 · How we verify

NCT02435238: AWARE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AWARE - Chronic Urticaria

Completed Last updated 15 February 2018

What this trial tests

trial in Chronic Urticaria in 180 participants. Completed in 27 September 2017.

Timeline

3 September 2014

Primary endpoint
27 September 2017

27 September 2017

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	180
Start date	3 September 2014
Primary completion	27 September 2017
Estimated completion	27 September 2017
Sites	21 locations across United Kingdom

Conditions studied

Chronic Urticaria — all drugs for Chronic Urticaria →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Chronic Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non interventional study collecting patient reported outcomes. The study aims to assess the disease burden of chronic urticaria patients and to record the therapies used in daily clinical practice in the UK and the impact they have on the quality of life and work productivity of individual patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02435238 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 15 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02435238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing